Baseline ECOG performance status 0 versus 1 as a modifier of treatment benefit from adding an immune checkpoint inhibitor to chemotherapy: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles